Chronic Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy (Q38766862)

6 September 2017

title

Chronic Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy (English)

1 reference

toxic epidermal necrolysis

6 September 2017

main subject

Stevens–Johnson syndrome

1 reference

based on heuristic

inferred from title

1 reference

James Chodosh

1 reference

6 September 2017

Victoria S Chang

1 reference

6 September 2017

George N Papaliodis

series ordinal

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 January 2016

1 reference

Seminars in Ophthalmology

6 September 2017

published in

1 reference

6 September 2017

1 reference

6 September 2017

issue

1-2

1 reference

6 September 2017

page(s)

178-187

1 reference

The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Management of acquired bullous skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Prevalence of chronic ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections in the cornea

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Elevation of conjunctival epithelial CD45INTCD11b⁺CD16⁺CD14⁻ neutrophils in ocular Stevens-Johnson syndrome and toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Conjunctival inflammation in the chronic phase of Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Chronic cicatrizing conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Neutrophil collagenase, gelatinase, and myeloperoxidase in tears of patients with stevens-johnson syndrome and ocular cicatricial pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Ocular surface inflammation mediated by innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Human mast cell subtypes in conjunctiva of patients with atopic keratoconjunctivitis, ocular cicatricial pemphigoid and Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Adverse reactions to dapsone in persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Adverse cutaneous reactions induced by TNF-alpha antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Keratoprosthesis in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Immunosuppressive therapy in inflammatory ocular surface disease post Steven Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Dapsone in the management of autoimmune bullous diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Dapsone in dermatology and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Treatment of ocular cicatricial pemphigoid with sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Recurrent erythema multiforme: clinical features and treatment in a large series of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Bronchiolitis obliterans associated with Stevens-Johnson syndrome and response to azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Toxic epidermal necrolysis-like cutaneous lupus erythematosus: A series of three patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Methotrexate for ocular inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Methotrexate--how does it really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Molecular mechanism of methotrexate action in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

The role of mycophenolate mofetil in kidney transplantation revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Recurrent erythema multiforme/Stevens-Johnson syndrome: response to mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Toxic epidermal necrolysis treated with cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Gene expression profiling of lung myofibroblasts reveals the anti-fibrotic effects of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Yin and yang in cytokine regulation of corneal wound healing: roles of TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Upregulation of tumor necrosis factor receptor 1 and TNF-alpha converting enzyme during corneal wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Critical role of TNF-α-induced macrophage VEGF and iNOS production in the experimental corneal neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Thalidomide in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Etoricoxib‐induced toxic epidermal necrolysis: Successful treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Intravenous immunoglobulin in critically ill adults: When and what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2015.1114841

10.3109/08820538.2015.1114841

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference